A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007112/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to provide continued access of ixazomib and/or other study
medications and to continue collecting relevant safety data to monitor participant's safety,
determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital
organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice
of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic
light chain (AL) amyloidosis.
提供机构：
Vivli
创建时间：
2021-05-06
